K36’s lead candidate is KTX-1001, a first-in-class, selective inhibitor of the histone methyltransferase (HMT) MMSET, which is overexpressed in up to 20% of multiple myeloma patients due to the t(4;14) translocation.

We developed KTX-1001 to provide a targeted therapy that specifically addresses the underlying cause of cancer for these multiple myeloma patients. KTX-1001 is the first therapeutic agent to enter the clinic that directly targets overexpression of MMSET.